Doctors & patients are saying about ''...

" is a great web site for patients, that is unequaled by anything else out there."

Dr. Douglas L. Packer, MD, FHRS, Mayo Clinic, Rochester, MN

"Jill and I put you and your work in our prayers every night. What you do to help people through this [A-Fib] process is really incredible."

Jill and Steve Douglas, East Troy, WI 

“I really appreciate all the information on your website as it allows me to be a better informed patient and to know what questions to ask my EP. 

Faye Spencer, Boise, ID, April 2017

“I think your site has helped a lot of patients.”

Dr. Hugh G. Calkins, MD  Johns Hopkins,
Baltimore, MD

Doctors & patients are saying about 'Beat Your A-Fib'...

"If I had [your book] 10 years ago, it would have saved me 8 years of hell.”

Roy Salmon, Patient, A-Fib Free,
Adelaide, Australia

"This book is incredibly complete and easy-to-understand for anybody. I certainly recommend it for patients who want to know more about atrial fibrillation than what they will learn from doctors...."

Pierre Jaïs, M.D. Professor of Cardiology, Haut-Lévêque Hospital, Bordeaux, France

"Dear Steve, I saw a patient this morning with your book [in hand] and highlights throughout. She loves it and finds it very useful to help her in dealing with atrial fibrillation."

Dr. Wilber Su,
Cavanaugh Heart Center, 
Phoenix, AZ

"...masterful. You managed to combine an encyclopedic compilation of information with the simplicity of presentation that enhances the delivery of the information to the reader. This is not an easy thing to do, but you have been very, very successful at it."

Ira David Levin, heart patient, 
Rome, Italy

"Within the pages of Beat Your A-Fib, Dr. Steve Ryan, PhD, provides a comprehensive guide for persons seeking to find a cure for their Atrial Fibrillation."

Walter Kerwin, MD, Cedars-Sinai Medical Center, Los Angeles, CA

2022 AF Symposium: Calculating Left Atrium Wall Thickness

Dr. Saman Nazarian

Spotlight Sessions feature products or devices still in development or not yet FDA approved. They give us a glimpse into the future of A-Fib treatments. This year 17 Spotlight products and treatments were presented in 5 minute talks. 

In this very short report from the 2022 AF Symposium, I summarize a 5-minute Spotlight session: “Personalization AF Ablation Based on CT Wall Thickness”.  Dr. Saman Nazarian, U of Penn, talks about use of Computerized Tomography (CT) to assist during a catheter ablation.

The Issue: The left atrium wall thickness varies from 1 mm to over 5 mm in the roof area. If one applies too much RF ablation power to a thin wall, this can produce steam pops, esophagus damage, or phrenic nerve damage. If too little RF energy is applied to thicker left atrium wall areas, this can lead to Pulmonary Veins (PV) reconnection….to continue reading, go to my very short report.

Personal A-Fib stories at

Go to Personal A-Fib stories of Hope

(Finally) A Head-to-Head Comparison of Anticoagulants for A-Fib: Eliquis vs Xarelto

The most commonly prescribed direct-acting anticoagulants (DOACs) for A-Fib patients are Eliquis (generic name: apixaban) and Xarelto (generic name: rivaroxaban).

Direct-acting anticoagulants (DOACs) were introduced in the early 2010s, but most of the testing has been against warfarin, not against other DOACs. Finally, thanks to the researchers of two retrospective studies, A-Fib patients now have a head-to-head comparison of Eliquis versus Xarelto.

Study 1: Stroke and Bleeding Risks

A recent retrospective study (Fralick, M. et al) looked at 6 years of prescription data for atrial fibrillation patients from the Nationwide Healthcare Claims Database (NPIC). A-Fib patient group sizes were matched (39,351 each). Mean age was 69 years, 40% were women and follow up was 288–291 days.

Significant Findings 

Eliquis patients had significantly lower incidence of major bleeding (12.9 vs 21.9 events-per-1K-person-yrs.)

1. Eliquis patients had significantly lower rates of stroke or systemic embolism (6.6 vs 8.0 events per 1000 person-years) compared to Xarelto.

2. Eliquis patients had a significantly lower incidence of major bleeding, defined as gastrointestinal bleeding or intracranial hemorrhage (12.9 vs 21.9 events per 1000 person-years).

Researchers Conclusion (Fralick, M. et al): In routine care, adults with atrial fibrillation prescribed apixaban had a lower rate of both ischemic stroke or systemic embolism and bleeding compared with those prescribed rivaroxaban.

Study 2: Stroke and Bleeding Risks

A second retrospective study (Ray, W. et al) looked at 581,451 atrial fibrillation patients 65 years or older who were enrolled in Medicare from 2013–2018. A-Fib patient group sizes were Rivaroxaban, 227,572 and Apixaban, 353,879. Follow up was for 4 years, through November 30, 2018. Mean age was 77.0 years; 50.2% were women (291 966).

Significant Findings 

Xarelto had substantially more nonfatal extracranial bleeding (39.7 vs 18.5 events-per-1K-person-yrs.)

1. Xarelto patients had more hemorrhagic events including fatal extracranial bleeding (1.4 vs 1.0 per 1000 person-years)

2. Xarelto had more nonfatal extracranial bleeding (39.7 vs 18.5 per 1000 person-years)

3. Xarelto had more fatal ischemic/hemorrhagic events (4.5 vs 3.3 per 1000 person-years)

4. Xarelto had more “total mortality” (44.2 vs 41.0 per 1000 person-years)

Researchers Conclusions and Relevance (Ray, W. et al):  Among Medicare beneficiaries 65 years or older with atrial fibrillation, treatment with rivaroxaban compared with apixaban was associated with a significantly increased risk of major ischemic or hemorrhagic events.

Eliquis vs Xarelto…and the Winner is…

Eliquis (apixaban)! In routine care, Eliquis was found to be both more effective and safer than Xarelto.

As patients, we should pay particular attention to the fact that Eliquis had significantly lower incidence of major bleeding (gastrointestinal bleeding or intracranial hemorrhage) than Xarelto (12.9 vs 21.9 events). And that Xarelto had increased nonfatal extracranial bleeding (39.7 vs 18.5 events) compared to Eliquis.

These differences in bleeding weren’t just “statistically significant” but were really alarming. Major, red flag warning important. Particularly for older people who are more prone to bleeding problems.

Alert: There is anecdotal evidence that some healthcare insurers are pushing patients to switch from Eliquis to Xarelto, despite the above research.

Be Your Own Best Patient-Advocate

Whether or not to take anticoagulants and which one is one of the most difficult decisions you and your doctor must make.

All the results cited above were “significant” and should be taken into account when choosing an anticoagulant.

If you are taking Xarelto, you should talk with your doctor about switching to Eliquis.

Learn all you can about your health conditions. A well-informed patient is welcomed by your doctors and healthcare caregivers. (If not, consider changing doctors.)
• Fralick, M. et al. Effectiveness and Safety of Apixaban Compared With Rivaroxaban for Patients With Atrial Fibrillation in Routine Practice: A Cohort Study. APC Journals, Annals of Internal Medicine. April 7, 2020.

• Ray, W. et al. Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients with Atrial Fibrillation. JAMA. 2021;326(23):2395-2404. doi:10.1001/jama.2021.21222

• Dressler, D. et al. Apixaban Might Be Safer and More Effective Than Rivaroxaban for Atrial Fibrillation. NEJM Journal Watch, Ann Intern Med 2020 Mar 9.

• The FH NPIC (National Private Insurance Claims) database. Includes information found on medical and dental claim forms for billions of services billed through private health insurance. 

• Dawwas, G.K. et al. Apixaban Versus Rivaroxaban in Patients With Atrial Fibrillation and Valvular Heart Disease—A Population-Based Study. Annals of Internal Medicine, 18 October 2022.


Can You Detect Atrial Fibrillation from Your Wallet?

AliveCor KardiaMobile Card

A-Fib patients! AliveCor, Inc. has announced the launch of their most advanced single-lead personal EKG, the KardiaMobile Card. An electrocardiogram (ECG) device the size of a standard credit card.

This easy to use technology records an accurate, medical-grade EKG and can detect 6 of the most common arrhythmias anytime, anywhere. It accurately detects A-Fib, Bradycardia, Tachycardia, PVCs, Sinus Rhythm with SVE, and Sinus Rhythm with Wide QRS.

The device’s algorithm is based on AliveCor’s Artificial intelligence-enabled (AI) Kardia technology, which has been evaluated by more than 170 peer-reviewed studies.

KardiaCare Membership: Purchase includes KardiaCare membership (first month free). KardiaMobile Card users have access to a cardiologist’s analyses of ECGs, monthly heart health reports, and automatic sharing of ECG recordings. Learn more at AliveCor KardiaMobile Card.

AliveCor KardiaMobile 6L

Want to Record Six-Lead EKGs?

AliveCor’s KardiaMobile 6L with KardiaCare gives you the power to record six-lead EKGs and detect 6 of the most common arrhythmias. It has two electrodes on the top for your fingers, and one on the bottom to contact the skin of your left leg and record a six-lead EKG.

KardiaMobile 6L delivers EKG leads I, II, III, aVL, aVR, and aVF. All without messy gels and wires.

Learn more at Alivecor KardiaMobile 6L with KardiaCare.

• AliveCor launches credit card sized ECG device. Cardiac Rhythm News, February 3, 2022. URL:

• AliveCor, Inc. Products. URL:

A-Fib Catheter Ablation Combined with Left Atrial Appendage (LAA) Closure

In the People’s Republic of China (and other countries) catheter ablation for Atrial Fibrillation is often combined with closure of the Left Atrial Appendage (LAA) in one procedure. This means A-Fib patients can have a Watchman occlusion device installed at the same time as their catheter ablation.

While it may be common practice in some locales, there is limited research data on this combined procedure and, in particular, with patients with prior stroke. That’s why this study in China was conducted.

There is limited research data on this combined procedure and, in particular, with patients with prior stroke.

Aim of this Study: To compare the safety and efficacy of combined catheter ablation with closure of the Left Atrial Appendage (LAA), especially for A-Fib patients who have had a prior stroke.

Study Design: This retrospective study enrolled 296 patients who underwent combined procedures of A-Fib catheter ablation and LAAC. Patients were divided into two groups: 81 patients with prior stroke (Stroke group) and 215 patients without prior stroke (Control group).

Combined procedures were successfully performed in all the patients.

Follow-up Findings: The researchers followed-up with patients at a mean of 20 months.

Both the Stroke group and the Control group (without prior stroke) were relatively A-Fib free after catheter ablation. (Stroke group: 64.2%, the non-stroke control group: 68.4%).

The relative risk reductions in stroke and bleeding were around 80% in the stroke group and 62% in the control non-prior stroke group.

Conclusion: The researchers wrote: “The combination of catheter ablation and LAAC (Left Atrial Appendage Closure) is safe and effective in selected AF patients with prior stroke.”

Editor's Comments about Cecelia's A-Fib storyEditor’s Comments

There are several limitations to this study. This is a single-center retrospective study with a moderate sample size.
Despite the limitations of this study, for A-Fib patients the combination of catheter ablation and Left Atrial Appendage (LAA) closure appears safe and effective.

Currently, U.S. patients have to wait 3 months after a catheter ablation to have a Watchman inserted. Why must patients wait, why endure months of anticoagulants usage? But, more research is needed to confirm the conclusions of these researchers.

Mo, B et al. Combined Catheter Ablation and Left Atrial Appendage Closure in Atrial Fibrillation Patients with and without Prior Stroke. Journal of Interventional Cardiology, Volume 2021, Article ID 2138670.


2022 AF Symposium: Pulsed Field Ablation Using a Focal Electrode Catheter

I’ve written a new report from the 2022 AF Symposium. The presentation included a video of the speaker performing the Pulsed Field Ablation. Note: PFA is not yet approved by the FDA, but is in clinical trials.

Dr. Atul Verma of Southlake Regional Health Center in Toronto, Canada presented his talk in a somewhat unusual format. He showed a pre-recorded case of him performing a Pulsed Field Ablation (PFA). Then while the video was playing, he would lower the volume and comment live to the audience. Several panelists and audience members also joined in offering comments during his presentation.

The Patient: Was in early persistent A-Fib, with a normal heart and normal-sized atrium. The goal was to isolate the patient’s Pulmonary Veins (PVs) and posterior wall using Pulsed Field Ablation (PFA).

The Ablation System: Dr. Verma performed an ablation of a patient using the Galaxy Centauri system. The Galaxy system allows EPs to use the same focal catheters and mapping systems they now use when they ablate using point-by-point Radio Frequency (RF) energy However, the Centauri generator produces PFA pulses instead of RF.

On the video, when Dr. Verma would make a point-by-point dot lesion using PFA…to continue reading my report. go to: Pulsed Field Ablation Using a Focal Electrode Catheter by Dr. Atul Verma.

For the background, concepts and treatment strategies associated with the evolving technology of Pulsed Field Ablation, see my 2020 AF Symposium report: Pulsed Field Ablation—Emerging Tech for Atrial Fibrillation.

What is the Annual International AF Symposium and Why is it Important to A-Fib Patients?

The past two decades have witnessed dramatic advances in all areas of A-Fib research with major progress in our understanding of atrial fibrillation and the development of safer and more effective strategies for the treating and curing of atrial fibrillation.

The annual International AF Symposium (formerly called the Boston AF Symposium) is one of the most important conferences on A-Fib in the world. The Symposium is a major scientific forum at which health care professionals have a unique opportunity to learn about advances in research and therapeutics directly from many of the most eminent investigators in the field.

AF Symposium presentation hall equipped with huge video monitors for panelists and via steaming video procedures.

This intensive and highly focused three-day symposium brings together the world’s leading medical scientists to share the most recent advances in the field of atrial fibrillation.

Why I Attend the Symposium Every Year

Each year I attend the Symposium to learn and ‘absorb’ the presentations and research findings.

Attending the annual AF Symposium gives me a thorough and practical view of the current state of the art in the field of A-Fib. I then apply this newly acquired knowledge and understanding to the publishing of

Prof. Michel Häissaguerre (who invented the PV ablation) and Steve Ryan at 2019 AF Symposium

Prof. Michel Häissaguerre (who invented the PV ablation) and Steve Ryan AF Symposium

Writing My Reports

On the plane ride home I start writing summaries of significant presentations and important research findings that are relevant to A-Fib patients and their families.

I strive to ‘translate’ as much of the medical jargon into everyday language. (My wife, Patti, keeps an eye out for this). I add my own comments and insights to help interpret the information for readers.

In the months following the Symposium, I write and post three or four reports each month usually ending up with about 12–20 articles. (Why does it take so long? I send each of my summaries to the presenter inviting their feedback, so it takes some time to get each article written, reviewed, and posted.)

I announce each posting on my A-Fib News Blog with a link to each article.

For the Readers of

My goal is to offer the most up-to-date A-Fib research findings and developments that may impact the treatment choices of patients seeking their A-Fib cure or best outcome.

OUR MISSION: At, we offer hope & guidance to empower patients to find their A-Fib cure or best outcome. is the patient’s unbiased source of well-researched information on current & emerging Atrial Fibrillation treatments.

Go to my list of 2022 AF Symposium Reports
or my AF Symposium Archives by Year

2022 AF Symposium: Pulsed Field Ablation Systems

At, we first described the new technology called Pulsed Field Ablation (Farapulse, Inc.) in the beginning of 2021. See my report: Pulse Field Ablation—Emerging Tech for Atrial Fibrillation. Since then, Farapulse, Inc. has been acquired by Boston Scientific.

Today many companies with different Pulse Field Ablation systems have entered the market. All are still in various stages of investigation, none have been FDA approved.

In my report, In Development: Systems for Pulsed Field Ablation (PFA), I summarize comments by Dr. Moussa Mansour of Massachusetts General Hospital in Boston, MA, in his presentation, “Technology and Regulatory Status of Current Systems for Pulsed Field Ablation (PFA).”

He gave an overview of the various companies and their PFA systems in development and in clinical trials. You’ll find my 2022 AF Symposium report here: Pulsed Field Ablation. You can also see my other reports at 2022 AF Symposium.

How Does LAA Closure for Atrial Fibrillation Affect Heart Pumping Ability?

Left Arial Appendage (LAA) closure is the cornerstone of stroke prevention in surgical treatment of A-Fib. The Left Atrial Appendage is closed off, cut out, stapled shut, or shut off with a clip. How does this affect the heart’s ability to pump blood?

Small Study to Directly Measure Pumping Effect of LAA Closure

In a very small study of the hybrid operation/ablation, seven patients were measured for cardiac output and left ventricular stroke volume just before the hybrid operation, directly after, then ten minutes later.

The hybrid operation/ablation, learn more at The Cox-Maze & Mini-Maze Surgeries and the Hybrid Surgery/Ablation

The researchers pointed out that “the LAA also has a contractile function and takes part in the LA contraction process, especially in patients in SR (sinus rhythm)”.

But five of the seven patients were in A-Fib and already had reduced ejection fraction (EF) (26%). (Normal EF is 50% to 75%.) Even in the patients in SR, their EF was only 46%.

Ejection fraction (EF) is a percentage of blood that is pumped out of the heart during each beat. A range of 50%-75% indicates your heart is pumping well, delivering an adequate amount of blood to the body and brain.

LAA Closure Lowers Pumping Pressure Long Term

The researchers pointed out that LAA closure “can result in lower systolic blood pressure on the long term” according to previous research. (“Systolic” is the top number in your blood pressure measurement and is the pumping force your heart exerts.)

The researchers also pointed out that the LAA is the predominant site of atrial natriuretic peptide (ANP) in the heart which can affect heart pumping “volume overload”.

No Significant Difference

The researchers found no significant differences in various pumping measurements, but the Left Ventricular Stroke Volume (LSCI) was affected (28 mLm² to 24 mLm², P-value 0.066).

Editor's Comments about Cecelia's A-Fib storyEditor’s Comments

Patients with Poor EF: In patients with poor heart pumping and contracting ability (EF below 50%) to begin with, this study suggests they aren’t affected much by losing their LAA. They probably wouldn’t even notice it was gone. But the jury is still out on how losing the LAA affects even A-Fib patients with poor Ejection Fraction (EF) long term.
Patients with Normal EF: However, this may not be the case with A-Fib patients with a normal EF. The LAA does have a contractile function, particularly in patients with larger size LAAs. (Do athletes have larger size LAAs due to their exercise?)  This small study did not address the cases of A-Fib patients with normal EFs.

What This Means for A-Fib Patients

This small study didn’t measure patients with a normal Ejection Fraction (EF) who had their Left Atrial Appendage (LAA) closed off or removed. Most likely the heart’s pumping ability is affected by losing one’s LAA. (In dogs, the LAA provides 17.2% of the volume of blood pumped by the left atrium.)
If you are an active exerciser or athlete, you may want to consider keeping your LAA if possible. But for most people, losing your LAA probably won’t affect you very much. You may not even notice your LAA is gone.

What this Means to Me: A Watchman in my Future

Personally, I love to run, do sprints, etc. But after two recent ablations (after 21 years of being A-Fib free), my Medtronic Reveal LINQ loop recorder recently picked up a full day of Silent A-Fib signals. (Reports are sent wirelessly to my EP each night by the bedside transmitter.)

This wasn’t a big surprise. In my last ablation, my LAA was ablated to stop A-Fib signals, but it also electrically affected the LAA from pumping out properly. My EPs warned me that I would likely need to close-off my LAA sometime in the future.

With this recent data, my two EPs (Drs. Doshi and Natale) recommended I close-off my LAA with a Watchman device.

Even though it might affect my pumping ability, at age 81, stopping my A-Fib signals is more important to me. After my Watchman implant, I’ll write more. 

For my first-hand account of having a Medtronic Reveal LINQ loop recorder, go to Has My A-Fib Returned? I Get an Insertable Wireless Monitor

Heuts, S. et al. Does Left Atrial Appendage Exclusion by an Epicardial Clip influence Left Atrial Hemodynamics? Pilot Results of Invasive Intra-Cardiac Measurements. JAFIB Journal of Atrial Fibrillation.

Catheter Ablation: Long-Term A-Fib Symptom Reduction and Improved Quality of Life

In an observational study from Sweden, researchers examined the long-term effects of catheter ablation after 5 years. They wanted to know if undergoing a catheter ablation would affect both A-Fib symptoms and health-related Quality of Life (HRQoL).

Catheter Ablation: Eliminated or Reduced A-Fib Symptoms

From 2011 through 2019, 1521 A-Fib patients had RF PVI catheter ablations at Swedish hospitals using primarily the Carto system. After 5 years, 52% reported freedom from symptoms, 18% reported a greater than 50% symptom reduction, 14% had a minor reduction, while 18% reported no effect or a worsening of symptoms. Over half of the patients who had a catheter ablation were free from arrhythmia-related symptoms.

Symptom Reduction: Of those A-Fib patients still reporting symptoms, more than 80% experienced a symptom reduction. Altogether, more than 80% of the study participants experienced an improved arrhythmia-related situation. Researchers wrote: “The positive effect of CA [catheter ablation] on symptoms is long-lasting.”

Re-Ablation Option: Some of those who did not improve or whose symptoms worsened were accepted for re-ablation at follow-up. After five years, the most commonly reported symptoms were: breathlessness during activity, weakness/fatigue, and tiredness.

Independent predictors: Of those who reported no or worse A-Fib effects at follow-up, independent predictors were:

• Female gender
• Obesity (Body mass index ≥ 35)
• Ischemic Heart Disease (IHD) (narrowed arteries).

At follow-up in the study, the researchers didn’t find any gender differences.

More About Women with A-Fib: In my article, Women with A-Fib: Mother Nature and Gender Bias, I discuss how women have a higher symptom burden and often experience a more negative Quality of Life.

Dramatic Improvement in Quality of Life After Catheter Ablation

Quality of life (HRQoL) was evaluated both before the catheter ablation and after 5 years.

I found the Quality of Life questionnaire (ASTA) to be comprehensive, well written, and easy for patients to fill out.

Patients reported Quality of Life by using a 13-item scale divided into a 7-item physical subscale and a 6-item mental subscale. (HRQoL scale score values ranged from 0 to 100. Higher scores reflected both a higher symptom burden and a worse effect on Quality of Life.)

Quality of Life score was significantly lower [better] 5 years after catheter ablation (36.7 vs 13.1).

Quality of Life was obviously influenced by A-Fib symptoms which can cause psychological and emotional effects. At baseline at the beginning of the study, the most commonly reported negative influences on Quality of Life (HRQoL) were physically related: impaired physical ability, deteriorated life situation, and feeling unable to carry out daily activities.

Patients also reported worry, uncertainty about potential side-effects of medication, risk of recurrence, and the possible need for repeat procedures.

These negative effects improved dramatically over five years. The negative influences on HRQoL were primarily in those still reporting the presence of arrhythmia.

The Elderly had the Same Improvement as Younger Patients

Older A-Fib patients (over age 75) reported the same significant improvement in the symptoms scale score as younger ones. Quality of Life (HRQoL) improved significantly over 5 years, without any differences found between gender or age group.

Editor's Comments about Cecelia's A-Fib storyEditor’s Comments:

Being “Elderly” Shouldn’t Stop You from Having a Catheter Ablation: Unfortunately, some centers have an age cutoff for catheter ablation at age 75 or 80. This Swedish study instead found that “patients with AF should not be excluded from CA solely because of age.” To learn more see my FAQs A-Fib Ablations: Is 82 Too Old for a PVA?
Catheter Ablation Produces Better Results Today: A-Fib is one of the easiest heart diseases to “cure”. Catheter Ablation (CA) today is one of the safest, most effective, life-transforming procedures you can have in a hospital (CA isn’t surgery, there is no cutting involved.)
Today’s advanced catheter ablation treatments and mapping would probably produce greater symptom reduction than in this study.
Important Study on Quality of Life: The authors are to be commended for studying how catheter ablation influences Quality of Life (HRQoL). (Anyone who has become A-Fib free can testify how transformative and life-changing it is to go from A-Fib to normal sinus rhythm, such as myself.)
For many A-Fib patients, the impact on Quality of Life is just as important as their symptoms.
When doctors talk with patients about catheter ablation, they usually concentrate on A-Fib symptoms.
Instead, more emphasis should be put on how catheter ablation can radically improve Quality of Life. In this Swedish study, the strongest, most dramatic results for patients were in improved Quality of Life.
For many A-Fib patients, the challenges and impact on Quality of Life are just as important as their symptoms.

Considering a catheter ablation for your Atrial Fibrillation? Learn more on our Treatments for A-Fib page: Catheter Ablation: Pulmonary Vein Ablation (Isolation) 

Walfridsson, U. et al. Symptoms and health-related quality of life 5 years after catheter ablation of atrial fibrillation. Clinical Cardiology. Clinical Investigations. Dec 16, 2021 doi: 10.1002/clc.23752


2022 AF Symposium: The LOOP Study–Implications for Clinical Practice

Last week, I published my Overview of the 2022 AF Symposium held in January in New York City. You can find it on my page, My Summary Reports Written for Atrial Fibrillation Patients.

The LOOP Study – Implications for Clinical Practice and Future Trials” was presented by Dr. Andrea Russo of Cooper University Hospital in Camden, New Jersey.

Dr. Andrea Russo

Dr. Andrea Russo

A-Fib Strokes More Dangerous: Dr. Russo described how one-third of strokes are due to A-Fib. And these strokes are more severe and debilitating than those not associated with A-Fib. Many were not diagnosed with Atrial Fibrillation until after they had a stroke or heart attack.

The LOOP Study Research: The researchers posed the questions: Is all A-Fib is worth seeing or worrying over? “Does all detected A-Fib require anticoagulation?” Is A-Fib lasting more than 6 minutes but less than 24 hours duration, really a threat?

From 4 centers in Denmark, study patients received the Medtronic Reveal LINQ LOOP Implantable Recorders (ILR), the Reveal LINQ to investigate…. continue reading The Loop Study.

Follow Us
facebook - A-Fib.comtwitter - A-Fib.comlinkedin - A-Fib.compinterest - A-Fib.comYouTube: A-Fib Can be Cured! -

We Need You Help be self-supporting-Use our link to Amazon is a
501(c)(3) Nonprofit

Your support is needed. Every donation helps, even just $1.00. top rated by since 2014 

Home | The A-Fib Coach | Help Support | A-Fib News Archive | Tell Us What You think | Press Room | GuideStar Seal | HON certification | Disclosures | Terms of Use | Privacy Policy